Correlates of subjective well-being in schizophrenic patients treated with atypical antipsychotics

International Journal of Psychiatry in Clinical Practice

Volumn 9, Issue 2, 2005, Pages 94-98

  Schimmelmann, B Graf ^a,b   Moritz, S ^a   Karow, A ^a   Schafer, I ^a   Bussopulos, A ^a   Golks, D ^a   Krausz, M ^a   Naber, D ^a   Lambert, M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Atypical antipsychotics; Schizophrenia; Side effects; Subjective well being

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; RISPERIDONE; ZOTEPINE;

ADULT; AMENORRHEA; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FEMALE; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MENORRHAGIA; MENTAL DISEASE; MENTAL PATIENT; MULTIPLE REGRESSION; NEGATIVE SYNDROME; NEUROTOXICITY; ORGASM DISORDER; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SCORING SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; WELLBEING;

EID: 21044456325     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500510018266     Document Type: Article

References (18)

1. De Haan L. Subjective experiences of patients with schizophrenia related to antipsychotic medication. In: De Haan L, editor. Patients' perspectives, subjective experiences and attitudes of patients with recent onset schizophrenia. Thesis, University of Amsterdam; 2001. p 105-14.
2. Allan ER, Sison CE, Alpert M, et al. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. Psychopharmacol Bull 1998;34:71-4.
3. Lambert M, Graf Schimmelmann B, Karo A, Naber D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - Concepts, measurement and clinical relevance. Pharmacopsychiat 2003;36(Suppl 3):181-90.
4. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationship to objective psychopathlogy, quality of life, compliance and other variables. Int Clin Psychopharmacol 1995;10(Suppl 3):133-8.
5. Schimmelmann BG, Schacht M, Perro C, Lambert M. The initial dysphoric reaction (IDR) followed the first neuroleptic dosage. Nervenarzt 2004;75:36-43.
6. Karow A, Czekalla J, Mahl C, et al. Subjective well-being under neuroleptic therapy: 6 month data from the Schizophrenia Outpatients Health Outcomes Study. AEP, 3rd European Conference on Psychotherapy, Heidelberg, 2003. p. 67.
7. Helmchen H. Prediction of course and therapeutic response in psychiatric disease. Pharmacopsychiat 1983;16:173-4.
8. Kane JM, Leucht S, Carpenter D. Expert consensus guidelines for optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64(Suppl):5-19.
9. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
10. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM) 76-338. Rockville, MD: National Institut of Mental Health; 1976.
11. American Psychiatric Association. Diagnostic Criteria from DSM-IV. Washington, DC: American Psychiatric Press; 1994.
12. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;334(Suppl):1-100.
13. Cabeza IG, Amador MS, Lopez CA, et al. Subjective response to antipsychotics in schizophrenic patients: Clinical implications and related factors. Schizophr Res 2000; 41:349-55.
14. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-9.
15. Gervin M, Browne J, Garavan M, et al. Dysphoric subjective response to neuroleptics in schizophrenia: Relationship to extrapyramidal side effects and symptomatology. Eur Psychiatry 1999;14:405-9.
16. Presser ES, Csernansky JF, Kaplan J, et al. Depression, parkinsonian symptoms and negative symptoms in schizophrenic treated with neuroleptics. J Nerv Ment Dis 1987;175:100-5.
17. Bilder RM. Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry 1997;42:255-64.
18. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002;57:209-19.